UNITED STATES
                      SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C. 20549

                               ________________
                                   FORM 8-K

                                CURRENT REPORT
    Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934


Date of Report (Date of earliest event reported)    March 14, 2005
                                                    ---------------------------


                          GENELABS TECHNOLOGIES, INC.
- -------------------------------------------------------------------------------
            (Exact name of registrant as specified in its charter)


          California                 0-19222                 94-3010150
- -------------------------------------------------------------------------------
(State or other jurisdiction   (Commission File Number)    (IRS Employer
  of incorporation)                                        Identification No.)


      505 Penobscot Drive, Redwood City, California             94063
- -------------------------------------------------------------------------------
        (Address of principal executive offices)             (Zip Code)


Registrant's telephone number, including area code       (650) 369-9500
                                                   ----------------------------


- -------------------------------------------------------------------------------
        (Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any of
the following provisions (see General Instruction A.2. below):

|_|  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

|_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
     CFR 240.14a-12)

|_|  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

|_|  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))






Item 2.02     Results of Operations and Financial Condition.

         On March 14, 2005, the registrant announced its 2004 year-end and
fourth quarter financial results. A copy of the press release is furnished as
exhibit 99.1 hereto.

         The information in this Form 8-K (including Exhibit 99.1) shall not
be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of
1934 (the "Exchange Act") or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933 or the Exchange Act, except as expressly set forth
by specific reference in such a filing.

Item 9.01     Financial Statements and Exhibits.

(c) Exhibits

99.1     Press Release of Registrant, dated March 14, 2005, entitled
         "Genelabs Technologies Reports 2004 Year-End and Fourth Quarter
         Financial Results."





                                  SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereto duly authorized.


                                               GENELABS TECHNOLOGIES, INC.


                                               By: /s/ Matthew M. Loar
                                                   ----------------------------
                                               Name:   Matthew M. Loar
                                               Title:  Chief Financial Officer
Date:  March 15, 2005